Diagnos

Diagnos FCF Margin

The Free Cash Flow Margin of Diagnos (ADK.V) as of Nov 2, 2026 is -5,749.38 %. In the previous year, Free Cash Flow Margin was -3,517.61 % — a change of 63.45% (lower).

FCF Margin

-5,749.38 %

YoY

63.45%

Last updated:

Free Cash Flow Margin of Diagnos is 2026 -5,749.38 % . Free Cash Flow Margin of Diagnos was 2025 -3,517.61 % . It decreases by 63.45% lower compared to the previous year.

The Diagnos FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2019
-723.50 CAD
Jan 1, 2020
-801.12 CAD
Jan 1, 2021
-523.82 CAD
Jan 1, 2022
-471.47 CAD
Jan 1, 2023
-392.80 CAD
Jan 1, 2024
-1,422.67 CAD
Jan 1, 2025
-3,517.61 CAD
Jan 1, 2026
-5,749.38 CAD
The Diagnos FCF Margin history
YEARFCF MarginYoY
-5,749.38 %+63.45%
-3,517.61 %+147.25%
-1,422.67 %+262.19%
-392.80 %-16.69%
-471.47 %-9.99%
-523.82 %-34.61%
-801.12 %+10.73%
-723.50 %+364.05%
-155.91 %+81.83%
-85.74 %-65.47%
-248.30 %-51.73%
-514.35 %+1,026.51%
-45.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Diagnos Stock analysis

What does Diagnos do? Diagnos Inc. generates revenue through its AI-driven healthcare technical services, primarily via FLAIRE, which enables application modification and development. The company offers CARA, a tool using image enhancement algorithms for sharper retinal images, supporting real-time screening of large patient volumes. Its key markets include Canada, the United States, Saudi Arabia, Mexico, Costa Rica, and Chile, with subsidiaries Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited serving these regions. Clients are healthcare providers seeking advanced diagnostic tools for efficient patient screening. CARA’s real-time capabilities and image clarity make it a preferred solution for clinics and hospitals managing high patient throughput. FLAIRE’s application development features cater to healthcare institutions needing customized AI integrations. The company’s geographical reach spans multiple countries, leveraging its subsidiaries to serve diverse healthcare systems. Revenue streams are tied to software licensing and service contracts for these AI-powered diagnostic tools. Diagnos Inc. focuses on providing specialized AI tools for ophthalmology, with CARA being central to its offerings. The company’s subsidiaries facilitate localized market penetration, ensuring compliance and adaptation to regional healthcare needs. Clients include medical facilities requiring accurate and efficient diagnostic solutions, particularly in regions with growing healthcare infrastructure. Diagnos is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Diagnos stock

Free Cash Flow Margin of Diagnos is -5,749.38 % in 2026.

Free Cash Flow Margin of Diagnos changed from -3,517.61 % to -5,749.38 %, representing a 63.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Diagnos since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Diagnos with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Diagnos

All Key Metrics — Diagnos